These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 22099782)

  • 21. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
    Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
    Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapy with anti-CD20 monoclonal antibody in a heart transplant recipient with sick sinus syndrome and posttransplantation lymphoproliferative disorder: a case report.
    Yang HY; Ke HY; Hong GJ; Tsai YT; Lin CY; Li CY; Tsai CS
    Heart Surg Forum; 2009 Oct; 12(5):E300-2. PubMed ID: 19833600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extreme hypercalcemia in a kidney transplant recipient.
    Demir E; Karaoglan C; Yegen G; Sair B; Yazici H; Turkmen A; Sever MS
    CEN Case Rep; 2018 Nov; 7(2):229-233. PubMed ID: 29705974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.
    Banks CA; Meier JD; Stallworth CR; White DR
    Ann Otol Rhinol Laryngol; 2012 May; 121(5):291-5. PubMed ID: 22724273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-Transplant Lymphoproliferative Disorder (PTLD) Manifesting in the Oral Cavity of a 13-Year-Old Liver Transplant Recipient (LTx).
    Krasuska-Sławińska E; Minko-Chojnowska I; Pawłowska J; Dembowska-Bagińska B; Pronicki M; Olczak-Kowalczyk D
    Ann Transplant; 2015 Aug; 20():478-82. PubMed ID: 26285106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
    Aimoto M; Yamane T; Inoue A; Momose D; Moriguchi-Aimoto R; Wada-Inoue E; Okamoto S; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Hino M
    Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation.
    Twombley K; Pokala H; Ardura MI; Harker-Murray P; Johnson-Welch SF; Weinberg A; Seikaly M
    Pediatr Transplant; 2012 Sep; 16(6):E201-9. PubMed ID: 22646132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():31-3, 35-6. PubMed ID: 12091638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
    Orjuela M; Gross TG; Cheung YK; Alobeid B; Morris E; Cairo MS
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3945S-52S. PubMed ID: 14506193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation.
    Suryanarayan K; Natkunam Y; Berry G; Bangs CD; Cherry A; Dahl G
    J Pediatr Hematol Oncol; 2001 Oct; 23(7):452-5. PubMed ID: 11878581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
    Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
    J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
    Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA
    Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
    J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
    Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
    Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.
    Dharnidharka VR; Douglas VK; Hunger SP; Fennell RS
    Pediatr Transplant; 2004 Feb; 8(1):87-90. PubMed ID: 15009846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.